Taga M

No ORCID on file · 5 papers in corpus
review 2001
[GnRH agonists in the treatment of endometriosis]
Nihon rinsho. Japanese journal of clinical medicine
nonrandomized-trial 1998
The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem.83.2.4565

To evaluate the clinical utility of recently developed biochemical markers in the assessment of bone metabolism during GnRH agonist (GnRHa) treatment, we compared five bone resorption markers [C-telopeptide (CTX) and N-telopeptide (NTX) of …

case-report 1997
Huge ovarian endometrial cyst: a case report
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(97)00115-2

We are reporting a rare case of a huge ovarian endometrioma, one as large as an adult head, and the difficulty of differential diagnosis regarding this ovarian tumor.

observational 1997
Prolactin secretion in endometriotic patients
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/s0301-2115(96)02649-8

OBJECTIVE: To clarify a significance of prolactin (PRL) for infertility in endometriosis. STUDY DESIGNS: For seventy endometriotic patients with or without infertility, serum PRL concentrations measured by radioimmunoassay before and 30 mi…

nonrandomized-trial 1996
Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
Acta obstetricia et gynecologica Scandinavica ·doi:10.3109/00016349609033310

STUDY OBJECTIVE: To determine the reversibility of bone mineral density after the cessation of GnRH agonist treatment for endometriosis. DESIGN: Longitudinal trial with 6-month treatment period and 6-month follow-up. PATIENTS: 28 Japanese…